By Diagnostics World News Staff
December 29, 2025 | Diagnostics is gaining growing traction within several companies not historically diagnostics-focused, and it is the subject of a fair amount of AI investment as well. NVIDIA’s partnerships with diagnostics companies came up in more than one top story of the year, and AI’s role for image processing came up in others. Even earlier multi-cancer early detection tests were notable and the growing trend in women’s health was reflected in attention to endometriosis diagnosis.
Read more for our list of the most-read articles of 2025.
GE HealthCare announced a collaboration in March with NVIDIA, expanding the existing 16-year relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound. Autonomous X-ray and ultrasound are promising new areas of development, using AI-enabled software to capture and analyze medical images, which could minimize the burden on technicians and radiologists. GE HealthCare aims to develop AI-enabled X-ray and ultrasound systems by leveraging the new NVIDIA Isaac for Healthcare platform, built on NVIDIA’s three computers utilized to build physical AI, including NVIDIA Omniverse for robotic simulation workflows. Using the NVIDIA Cosmos platform for synthetic data generation, physics-based sensor simulation, imitation, and reinforcement learning, GE HealthCare plans to train, test, and tune autonomous ultrasound and X-ray devices in a virtual environment before deployment in the physical world. Read more.
Researchers worldwide are looking to revamp traditional approaches to medical imaging and develop alternative solutions that could improve visualization, speed, and accuracy in diagnostic settings. At the University of Arkansas, for example, one group is developing an AI tool designed to help radiologists and doctors analyze chest X-rays and computed tomography (CT) scans, with an emphasis on understanding how the AI assistant arrives at its conclusions. University of Houston researchers are pursuing a new 3D x-ray approach to identify bone and soft tissue damage. And researchers in Japan have developed a respiratory motion monitoring system for X-ray imaging and CT scans. Their millimeter-wave sensor (MWS) technology uses electromagnetic radiation to detect motion during diagnostic imaging procedures without any physical contact, which they say helps with patient comfort and privacy. Read more.
At the 2025 J.P. Morgan Healthcare Conference, Masoud Toloue, CEO of Quanterix, presented his company’s achievements of 2024, the acquisition of Akoya Biosciences, and their plans for the new year. He highlighted the company’s foundational platform Simoa, which allows users to look at biomarkers in blood with ultra-sensitivity. Read more.
Efforts to find cancer early have been ongoing for more than a century now, but proven screening tests are available only for a handful of the most common types of malignancies and don’t always produce accurate results. Multi-cancer early detection (MCED) tests have emerged over the last decade that detect many different cancers in a single assay, but they excel only at the detection of cancer at stage three or four. A growing number of promising young companies are now developing tests that are particularly good at picking up early cancer, initially for a single type of cancer but with the potential to eventually be extended to multiple cancer types. Read more.
The incidence of bladder cancer is rising significantly due to population aging and, while survival rates are relatively high, when diagnosed late patients may need to undergo bladder removal regardless of survival. Early detection and treatment of bladder cancer are therefore crucial to preserving the organ and maintaining the patient’s quality of life, according to Youngdo Jeong, Ph.D., principal research scientist with the Center for Advanced Biomolecular Recognition at the Korea Institute of Science and Technology. Read more.
The clinical relevance and limitations of so-called “lab-in-a-box” (LIAB) diagnostics, which surged in popularity during the COVID pandemic, have since that time been under considerable scrutiny, most notably among investors still spooked by the notorious Theranos scandal. One of the more enduring problems among LIAB developers is that they tend to get “blinded by the beauty” of their technology, according to Larry Worden, principal and founder of marketing research and consulting firm IVD Logix. Far too often, they never stop to consider what critical unmet need their system or specific assay is going to fill. Read more.
Among the many partnerships and technical announcements made by NVIDIA during the company's presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry. Pathology has long been an early adopter of AI in computer vision, and NVIDIA plans to continue pushing that forward with a collaboration with Mayo Clinic. Mayo’s Clinic Digital Pathology platform, built from autonomous robotic labs and advanced imaging technology, already hosts a dataset of 20 million whole-slide images with 10 million associated patient records. Mayo Clinic and NVIDIA will work together to accelerate the development of the pathology foundation models using these data. Read more.
Endometriosis occurs when tissue similar to the lining of the uterus grows outside of the uterus. The condition is painful, can impede fertility, and is difficult to diagnose. But a host of new tools seek to improve diagnostics and treatment for the condition. Cicero Diagnostics, a Nevada-based company, has announced the release of its MyReceptiva endometriosis detection test, designed to identify patients who are likely to have the condition and would benefit from consulting with an endometriosis specialist. Meanwhile, Boston-based Heranova Lifesciences revealed the Laboratory Developed Test (LDT) validation and U.S. launch of HerResolve, a blood test that will initially be available through select clinical centers. Read more.